Abstract:The advancement of cancer‐fighting drugs has never been a simple linear process. Those drug design professionals begin to find inspiration from the nature after failing to find the ideal products by creative drug design and high‐throughput screening. To obtain new molecules for inhibiting tubulin, podophyllotoxin was adopted as the leading compound and 1,3,4‐oxadiazole was brought in to the C‐4 site of podophyllotoxin in this research. A series of seventeen podophyllotoxin‐derived esters have been achieved and then evaluated their antitumor activities against four different cancer cell lines: A549, MCF‐7, HepG2, and HeLa. Among all the compounds, compound 7c showed the best antiproliferating properties with IC50 = 2.54 ± 0.82 μm against MCF‐7 cancer cell line. It was obvious that the content of ROS grew significantly in MCF‐7 in a way depending on the dosage. The time‐ and dose‐dependent cell cycle assays revealed that compound 7c could apparently block cell cycle in the phase of G2/M along with the upregulation of cyclin A2 and CDK2 protein. According to further studies, confocal microscopy experiment has certified that compound 7c could restrain cancer from growing by blocking the polymerization of microtubule. Meanwhile, compound 7c could be ideally integrated with the colchicine site of tubulin. In future, it would be feasible to selectively design tubulin inhibitors with the help of 3D‐QSAR. This means that it is hopeful to develop compound 7c as a potential agent against cancer due to its biological characteristics.

A recent antitumor story of podophyllotoxin derivatives targeting tubulin: an update (2017-2022)

Biological evaluation and molecular modelling study of podophyllotoxin derivatives as potent inhibitors of tubulin polymerization.

Design, synthesis and biological evaluation of novel podophyllotoxin derivatives as tubulin-targeting anticancer agents

An Update on the Recent Advances and Discovery of Novel Tubulin Colchicine Binding Inhibitors.

Design, Synthesis, Biological Evaluation, and 3D-QSAR Analysis of Podophyllotoxin-Dioxazole Combination As Tubulin Targeting Anticancer Agents.

Synthesis and Biological Evaluation of a Series of Podophyllotoxins Derivatives As a Class of Potent Antitubulin Agents.

A review of research progress of antitumor drugs based on tubulin targets

Discovering Podophyllotoxin Derivatives As Potential Anti‐Tubulin Agents: Design, Synthesis and Biological Evaluation

Synthesis and Evaluation of Novel Podophyllotoxin Derivatives As Potential Antitumor Agents.

Insight Into the Molecular Mechanism of Podophyllotoxin Derivatives as Anticancer Drugs

Design, Synthesis and Antitubulin Activity of Novel Podophyllotoxin Derivatives As Potent Anticancer Agent

Recent progress on tubulin inhibitors with dual targeting capabilities for cancer therapy

Recent advances of podophyllotoxin/epipodophyllotoxin hybrids in anticancer activity, mode of action, and structure-activity relationship: An update (2010–2020)

Podophyllotoxin: Recent Advances in the Development of Hybridization Strategies to Enhance Its Antitumoral Profile

Design, Synthesis and Anti-Cancer Evaluation of Novel Podophyllotoxin Derivatives As Potent Tubulin-Targeting Agents

Novel Podophyllotoxin Derivatives as Potential Tubulin Inhibitors: Design, Synthesis and Anti-proliferative Activity Evaluation.

Development of tubulin polymerization inhibitors as anticancer agents

Advances of podophyllotoxin and its derivatives: Patterns and mechanisms

Discovery of Novel Isoquinoline Analogues as Dual Tubulin Polymerization/V-ATPase Inhibitors with Immunogenic Cell Death Induction

Tubulin Inhibitors Binding to Colchicine-Site: A Review from 2015 to 2019